The phenomenon of tumour associated hypoglycaemia is now well established as a form of non-insulin dependent fasting hypoglycaemia generally coincident with the presence of large mesenchymal tumours (Kahn, 1980 (Hill et al., 1987) . Elevated levels of IGF mRNA have been found in tumour types often associated with hypoglycaemia, e.g. liposarcoma and leiomyosarcoma (Tricoli et al., 1986; Hoppener et al., 1988) , and an elevated concentration of IGF has been reported in patients with hypoglycaemia (Gordon et al., 1981).
The phenomenon of tumour associated hypoglycaemia is now well established as a form of non-insulin dependent fasting hypoglycaemia generally coincident with the presence of large mesenchymal tumours (Kahn, 1980) . The effect is most commonly seen in adults between the ages of 40 and 70, and most frequently with tumours such as fibrosarcoma and rhabdomyosarcoma, although it has been reported with hepatoma and adrenal cortical carcinoma. A plethora of mechanisms have been suggested to explain how tumours of this nature influence glucose homeostasis. At the most simple level, the observation that hypoglycaemia usually occurs when the tumour has reached a very large size, suggests that the high rate of glycolytic metabolism of tumour tissue might lead to a critical depletion of circulating glucose. However, no evidence has been presented as to the rate of glucose uptake by such tumours. A more persuasive explanation is that the tumour is producing small diffusible molecules, such as peptides, which mimic the effect of insulin. Obvious candidates for this role are the insulin like growth factors. The IGFs are single chain polypeptides, evolutionarily related to insulin, which exert a wide range of pleiotropic effects on their target cells. At high concentrations they share the anabolic effects of insulin, via the insulin receptor, but at normal physiological concentrations IGFI and II act via their own receptors to promote cell growth multiplication and differentiation in different systems (Hill et al., 1987) . Elevated levels of IGF mRNA have been found in tumour types often associated with hypoglycaemia, e.g. liposarcoma and leiomyosarcoma (Tricoli et al., 1986; Hoppener et al., 1988) , and an elevated concentration of IGF has been reported in patients with hypoglycaemia (Gordon et al., 1981) .
A recent report claimed that elevated levels of insulin-like growth factor II were responsible for hypoglycaemia in patients with leiomyosarcoma, and suggested that such aberrent expression of IGFII might contribute to tumour formation. However, several groups have been unable to show elevation of either IGF protein in patients' serum (Widmer et al., 1983; Merimee, 1986 , Haselbacher et al., 1987 . We report here a study of a female patient with a para-ovarian sarcoma associated with spontaneous hypoglycaemia. Levels of tumour IGFII mRNA were elevated around 30-fold with respect to normal tissue or human fibroblasts, whereas levels of IGFI or insulin mRNAs were low and undetectable respectively. However, assay of serum showed a suppression of IGF activity and tumour cyst fluid was found to contain little IGF.
A 57-year-old woman presented with attacks of confusion and drowsiness in the morning relieved by food. Fasting hypoglycaemia, with plasma glucose 1.5-2.1 mmol l-' was accompanied by low plasma insulin, 0.6 mU I', C-peptide 0.01 nmol l' (normal range: insulin, 3-12 mUI1'; C-peptide, 0.2-0.8 nmol 1'), which excluded an insulinoma. A CT scan showed a large left iliac fossa mass and at operation a large mucinous tumour with cysts was excised except for infiltration of the sigmoid colon and small bowel. Postoperatively she was normoglycaemic. Histology showed a malignant sarcoma. Plasma samples were taken for an IGF assay after an overnight fast, before the operation and after recovery from the operation. At operation tumour cyst fluid was aspirated for IGF assay. Fragments of tumour were put into primary tissue culture, and the supernatent assayed for IGFs.
RNA was prepared from fresh tumour tissue as described in (Hyldahl et al., 1986) , and Northern blot and SI nuclease protection assays as in (Schofield & Tate, 1987) . The probe used for the Northern analysis was the Hinfl-Pstl fragment of pHepS (Schofield & Tate, 1987) , containing only coding region sequence. The S1 analysis probes are described in the above reference, and consisted of the AvaII-PvuII fragment of pHIGFII labelled at the AvaII site in exon E2 of the IGFII gene using T4 polynucleotide kinase in the presence of T-32P ATP. The insulin probe was the kind gift of Dr Graham Bell (Bell et al., 1979) , and the IGFI probe of Prof. J. Scott (Bell et al., 1984) . Radioimmunoassay of IGFI and II was carried out according to Zapf et al. (1981) . 6.0 and 4.8 kb, which qualitatively resemble the RNA sizes from extrahepatic transcription during adult and fetal life. The quantity of transcripts, however, is much more similar to that seen in fetal tissue, representing a 30-fold increase in transcript levels as compared to normal fibroblasts, and higher than any normal adult tissue so far examined (Schofield & Tate, 1987; Scott et al., 1985) . S1 nuclease protection analysis was carried out to determine which of the three known IGF promoters was used in this tumour. The presence of a protected fragment of 214 bp in Figure 2 demonstrates that the major promoter is El(l), high levels of expression from which are characteristic of fetal tissues. Further analysis (not shown), using a single stranded probe crossing the position of alternative splicing at Ser 26 which inserts a tetrapeptide into the sequence, suggests that the variant IGFII (Jansen et al., 1985) is beneath the levels of detection. The group of bands visible at 143bp in the long exposure shown in Figure 2 indicate a small proportion of alternative 5' ends derived from the 'hepatic' promoter of IGFII. A small proportion of these transcripts are frequently seen in non-hepatic tissues.
Results of IGF radioimmunoassay are shown in Table I Figure 2 S1 nuclease protection analysis of sarcoma and other RNA samples. 10 1tg of total RNA was hybridised to end labelled probe, as described in Materials and methods, digested with S1 nuclease and electrophoresed along with end labelled 123bp ladder of DNA fragments. (Widmer et al., 1983; Merimee, 1986) . Postoperatively, both levels become normal. Neither the tumour cyst fluid or the primary tissue culture supernatant had high levels of IGFI or II. This is the first report of tumour associated hypoglycaemia in which both IGF mRNA and plasma and tumour cyst fluid IGF concentrations have been measured in the same patient. We have identified a paradoxical situation in which IGFII mRNA is substantially elevated in the tumour, but peptide levels are suppressed in both tumour cyst fluid and serum. This raises questions about the post transcriptional expression of the IGFII gene. Haselbacher et al. (1987) have previously reported increased mRNA but not IGFII peptides in a series of Wilm's tumours, and a careful systematic study of the ratio of peptide to mRNA for both IGFI and II by Han et al. (1988) supports the notion that at least some of the mRNAs derived from the IGFII transcription unit are translated poorly if at all. Alternative explanations might be that all the IGFII produced by the tumour was either not secreted or rapidly internalised by tumour cell receptors and never exchanged into bulk medium. This hypothesis would be very difficult to test, but strongly suggests that in cases where it is proposed that autocrine growth is induced by inappropriate tumour growth factor production, all measurements of mRNA for the factor should be accompanied by assay of protein production.
A recent report (Daughaday et al., 1988) suggested that tumour hypoglycaemia associated with a case of leiomyosarcoma was due to an increased proportion of a high molecular weight form of IGFII, present both in the circulation and in the tumour. Preoperative levels of acid/ethanol extractable IGF were low/normal in this patient, and the large molecular weight form of IGFII may represent a partially processed or unprocessed form of the molecule. In the case studied by us, lack of substantial quantity of total IGFII in tumour cyst fluid suggests that the tumour was not acting as a source of IGFII, and indicates that the hypoglycaemia was not due to circulating IGFII of tumour origin. However, we cannot rule out the possibility of an increased proportion in serum of 'big' IGFII from a different source, such as the liver. The antiserum used against IGFII is known to cross-react with partially processed pro-forms of IGFII, '10 kDa IGFII' (Zumstein et al., 1985) , excluding this from the possible mediators of hypoglycaemia.
The effective supression of levels of both IGFs, and their rapid recovery postoperatively are most likeiy a consequence of the hypoglycaemia. The serum concentrations of the IGFs, particularly IGFII, are sensitive to the concentration of both insulin and in the case of IGFI, growth hormone, and it seems likely that the low insulin levels induced by the hypoglycaemic state are responsible for the lowering of serum IGFs (Phillips & Untermin, 1984 
